VolitionRX Ltd (NYSEAMERICAN:VNRX) major shareholder Corp Ltd Eight bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were acquired at an average cost of $5.95 per share, for a total transaction of $297,500.00. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Corp Ltd Eight also recently made the following trade(s):
- On Thursday, September 26th, Corp Ltd Eight sold 46,238 shares of VolitionRX stock. The stock was sold at an average price of $6.03, for a total transaction of $278,815.14.
Shares of VNRX opened at $5.68 on Friday. VolitionRX Ltd has a fifty-two week low of $1.67 and a fifty-two week high of $6.84.
An institutional investor recently raised its position in VolitionRX stock. Ladenburg Thalmann Financial Services Inc. raised its position in VolitionRX Ltd (NYSEAMERICAN:VNRX) by 44.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,500 shares of the medical research company’s stock after purchasing an additional 10,000 shares during the period. Ladenburg Thalmann Financial Services Inc. owned 0.08% of VolitionRX worth $102,000 as of its most recent filing with the Securities and Exchange Commission.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Featured Article: Catch-Up Contributions
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.